

ANNEX 8. LIST OF ANTI-H1 ANTIHISTAMINES WITH A FRENCH MARKETED AUTHORIZATION FOR URTICARIA

INTERNATIONAL NON-PROPRIETARY NAME	AGE	HALF-LIFE	DOSE ADJUSTMENT ^a	RISK OF TORSADES DE POINTE ^b
FIRST GENERATION				
BROPHENIRAMINE	≥ 12 years	25 hrs	RI HI	-
CYPROHEPTADINE	≥ 6 years	10-15 hrs	RI	-
DEXCHLORPHENIRAMINE	≥ 6 years	14-25 hrs	RI HI	+
HYDROXYZINE	≥ 30 months	11-20 hrs 4 hrs (children)	RI HI Elderly patients	+++
MEQUITAZINE	≥ 6 years	18 hrs	HI	+++
PROMETHAZINE	Adult	10-15 hrs	RI HI	+++
SECOND GENERATION				
BILASTINE	≥ 12 years	14.5 hrs	RI	++
CETIRIZINE	≥ 2 years	10 hrs	RI (if cl<80 ml/min) Elderly patients	-
DESLORATADINE	≥ 1 year	27 hrs	RI Elderly patients	+
EBASTINE	≥ 12 years	15-19 hrs	RI	++
FEXOFENADINE	≥ 12 years	11-15 hrs	RI	+
LEVOCETIRIZINE	≥ 6 years	7.9 hrs	RI (if cl<80 ml/min) HI Elderly patients	-
LORATADINE	≥ 6 years	8.4 hrs	HI Elderly patients	-
MIZOLASTINE	≥ 12 years	13 hrs	HI	++
RUPATADINE	≥ 12 years	5.9 hrs	RI HI	+

a = adapt dose if: RI = renal insufficiency (cl<60 ml/min); HI = hepatic insufficiency

b = torsades de pointe: +++ = major proven risk; ++ = low risk; + = suspected risk; - = no risk to date

*c = the syrup form will soon be taken off the market (the minimum age will be raised from 2 to 6 years)
(source: base-donnees-publique.medicaments.gouv.fr)*

*d = the syrup form will soon be taken off the market (the minimum age will be raised from 2 to 12 years)
(source: base-donnees-publique.medicaments.gouv.fr)*